Other

NR566 Week 2 Ch 42, 43, & 45 Complete Study Guide

13 views 0 purchase

Course
AIT Nursing (NR566)

Institution
Thompson River University (TRU )

[Show more]

Preview 2 out of 11 pages

View example

Uploaded on February 11, 2021
Number of pages 11
Written in 2020/2021
Type Other
Person Unknown

nr 566 week 2 ch 42
43
nr 566 week 2 ch 42
43
and the host defen
amp 45 chapter 42 pneumonia
amp 45
chapter 42 pneumonia
etiology  pna develops when an organism invades the lung parenchyma

Welch1 Member since 6 year 61 documents sold

CA$17.21

Added

Add to cart Add to wishlist

100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached

NR 566 Week 2 Ch 42, 43, & 45
Chapter 42: Pneumonia

Etiology
 PNA develops when an organism invades the lung parenchyma, and the host defenses are
depressed.
 Chronically ill patients of all ages are more prone to PNA

Diagnosis
 PNA should be considered in any patient who presents with respiratory symptoms such as
cough, dyspnea, or sputum production.
 Fever or abnormal breath sounds (crackles) would strengthen the suspicion for PNA
 CxR- to confirm the dx of PNA

Classification
 Typical
o Caused by S. pneumoniae, H. influenzae, S. aureus, or gram-negative bacteria
o S/Sx:
 fever, chills
 yellow or green sputum
 pleuritic chest pain
 (+) lobar consolidation on CxR

 Atypical
o Caused by M. pneumoniae, Legionella pneumophila, viral infection
o S/Sx:
 Gradual onset of cough
 No or scant sputum
 Low-grade fever
 Myalgias
 Arthralgias
 (-) consolidation on CxR

Therapy and Goals of Treatment
 GOAL: return to the respiratory status a patient had before the illness
o Improved clinical condition in 48-72hrs after empirical abx tx
o Fever should resolve in 2-4 days
o Leukocytosis usually resolves by day 4 of tx
o NOTE: clear CxR is not an indicator of successful tx (may take time to be normal)
 Children: 6-8 weeks
 <50 yo: within 4 wks
 Older patients w/ comorbidity: on 4th week of tx

Common Bacterial Pathogens
 Streptococcus pneumonia- predominant organism (60%-75% for adults) except neonates.
 Haemophilus influenzae and Moraxella catarrhalis- common pathogens in patients with
underlying lung disease

,  Staphylococcus aureus- common co-pathogen in influenza-associated PNA
 Mycoplasma pneumoniae- pathogen difficult to detect on Gram’s stain or culture, is another
common cause of PNA

Clinical Practice Guidelines for CAP Treatment
 A practitioner will determine whether a patient needs an outpatient vs. inpatient treatment
 Criteria for hospital admission for PNA:
o RR >30
o T >101 F
o PaO2 <60 mmHg or PaCO3 >50 mmHg on RA
o Co-morbidities: DM, COPD, chronic renal failure, CHF, chronic live disease, ETOH abuse,
malnutrition (all these increase mortality of PNA)
o Age >65 yo

 Guideline in decision making for outpt vs. inpt
o Severity-of-illness scale: CURB-65 or PORT/PSI Score
 CURB-65:
 confusion, uremia, RR, low BP, age 65yo or above
 score of 2 and above = INPATIENT

o over-all clinical presentation (in the absence of guidelines)

 INITIAL EMPIRIC THERAPY:
o GROUP 1: Previously healthy outpatient with no cardiopulmonary disease, no abx in the
past months (no risk for DRSP), and no modifying factors:
 FIRST LINE: Azithromycin or clarithromycin (Erythromycin is less expensive but
can cause GI upset)
 Azithromycin 500mg on day 1, then 250mg daily on days 2 and 3
 Clarithromycin 250mg-500mg BID x 7-10 days
 Erythromycin 500mg QID x 7-10 days (250mg QID if gi upset occurs)

 SECOND LINE: doxycycline
 Treatment should not be altered for 72hrs!
 CAP- minimum 5 days treatment
 Patient should exhibit clinical response in 48-72hrs
 Patient should be afebrile for 48-72hrs.

o GROUP 2: Presence of comorbidities, immunosuppression, previous abx use for the last
3 months, other risk for DRSP infection:
 FIRST LINE: fluroquinolones (levofloxacin, moxifloxacin, gemifloxacin)
 SECOND LINE: beta lactam + macrolide
 Preferred choice: high dose of amoxicillin (1gm TID) or
amoxicillin/clavulanate (Augmentin)
 Alternatives: cefpodoxime, cefuroxime, IV ceftriaxone followed by PO
cefpodoxime
 Doxycycline- can be an alternative to macrolide

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller Welch1. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for CA$17.21. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

79271 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling

Other

NR566 Week 2 Ch 42, 43, & 45 Complete Study Guide

Document information

Subjects

Written for

Seller

Reviews received

Content preview